1. Diagnóza a prvá liečba rakoviny pľúc
Pacientke Lu bol diagnostikovaný pľúcny adenokarcinóm a metastáza lymfatických uzlín 26. augusta 2005. 22. septembra 2005 bola vykonaná ľavá dolná lobektómia. Po operácii bola 4-krát použitá karboplatina kombinovaná s taxoterom. 3. augusta 2007 sa v dôsledku pleurálneho výpotku potvrdila opakovaná diagnóza a bola liečená Tarcevou (počet cyklov nie je známy). 8. januára 2008 bol na opätovnom vyšetrení zistený progres rakoviny a následne bola liečba Tarcevou ukončená a liečba Libita bola zahájená na 16 cyklov. Zároveň bola zistená metastáza v bedrovom kĺbe a boli vykonané 4 cykly Zetai.
2. Pri prvej účasti na klinických skúškach je stav pod kontrolou.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the nádor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. V druhom klinickom skúšaní nádor evidentne zmizol.
On August 6, 2012, Mr. Lu participated in the AP26113 drug Klinická štúdia at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the nádor v mozgu decreased and became large.
4. Objavte vzácne génové mutácie a tešte sa na účasť v nových klinických štúdiách
Opätovné vyšetrenie v júli 2014 ukázalo PET celého tela: Mozgové lézie boli v podstate stabilné a hrudník mal zjavný pokrok. 12. mája 2014 sa v Massachusetts General Hospital uskutočnili podozrivé anti-AP26113 lymfatické (3 bunky, najväčšia 1.1 cm) kultivované bunkové línie a pokračovalo sa v užívaní AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastómu and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody imunoterapia phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
